HIMS , explosive revenue and subscriber growth; already exceeding guidance, dominance in high growth telehealth and lifestyle drug markets with relentless innovationAt a RS Rating of 98,
I have reasons to believe that this equity can increase in price
(Now in white chart canvas!)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.